IBEX Technologies, Inc.

BOSTON--( BUSINESS WIRE )-- Ibex Medical Analytics (Ibex), the leader in artificial intelligence (AI)-powered cancer diagnostics, today announced the findings of its inaugural Patient Insight Report on Cancer Diagnostics. The survey explores patients’ perceptions of receiving medical diagnoses, particularly for cancer. The survey results underscore the importance of advanced cancer diagnostic technologies, as well as accurate test results, and gauges respondents’ comfort with AI. “Patients should never have to question the validity of their test results; it’s scary enough to endure the burden of wondering if their life is about to change due to a pending cancer diagnosis,” said Joseph Mossel, CEO at Ibex. “The findings of our inaugural survey emphasize the urgent need for a united, steadfast commitment by all stakeholders to innovation and patient care to transform the standards of cancer diagnosis because we, as the healthcare community, owe patients accurate and timely test results every time.” Key findings from the report, conducted online from August 1 to 5, 2024, with 2,000 U.S. adults, reveal that: Americans harbor fear about cancer diagnoses Many Americans are worried about cancer, including fears about receiving a cancer diagnosis and, potentially, a misdiagnosis. Overall, 62% of Americans are concerned that they or a loved one will be diagnosed with cancer in the near future. Additionally, over half of the respondents (51%) reported being concerned that they or a loved one will receive a misdiagnosis of not having cancer when they do, with Gen Z (55%), Millennials (60%), and Gen X (50%) more likely than Baby Boomers (39%) to have these concerns. Trust in the diagnosis is paramount for patients Regarding patients’ views on the use of diagnostic technology, approximately nine in 10 (89%) respondents reported a need for better technology to help diagnose cancer, with a majority (60%) reporting feeling comfortable with AI supporting their doctor in making their cancer diagnosis. Patients are also willing to invest in another set of eyes, with 80% reporting a willingness to pay for a second opinion from a specialist in the specific type of cancer being evaluated. “The data underscores the critical need for both patients and providers to have access to the best possible resources in cancer diagnostics. Patients expect top-notch care and technology, and AI-powered diagnostics and digital pathology are essential tools in meeting these expectations today,” said Mossel. Receiving incorrect test results happens at an alarming rate Over half (59%) of respondents or their acquaintances have received incorrect medical test results. Notably, 7% reported that either they or a loved one received a negative diagnosis when it was actually cancer, and 6% were wrongly diagnosed with cancer. These figures reinforce concerns about the accuracy of the diagnostic process. Despite these issues, 88% of respondents remain mostly confident in the accuracy of their results. While 85% believe cancer diagnoses are generally correct, 68% typically do not seek a second opinion on medical test results. This lack of follow-up underscores the critical need for advanced diagnostic technologies to ensure accuracy, as obtaining a second opinion on a negative test result isn’t always a priority. Wait times are a major source of anxiety In addition to accuracy, the results also validated a need for greater efficiency in the diagnostic process, with 50% reporting feeling anxious about prolonged wait times for receiving cancer test results. Additionally, 80% of respondents reported that waiting for medical test results is very stressful. Of note, 88% of respondents agreed that there should be a way to speed up cancer testing so they can get the results in a day or so. The survey, commissioned by Ibex, garnered insights from 2,000 U.S. adults aged 18 and older. To learn more about its findings, download the Patient Insight Report on Cancer Diagnostics . For additional information, please visit ibex-ai.com, LinkedIn and X . About Ibex Medical Analytics Ibex Medical Analytics is transforming cancer diagnostics with world-leading clinical grade AI-powered solutions for pathology. Empowering physicians and supporting pathologists, Ibex is on a mission to provide accurate, timely and personalized cancer diagnosis for every patient. Ibex is the first and most widely deployed AI-powered platform in pathology. Pathologists worldwide use Ibex as part of their everyday routine to improve the accuracy of cancer diagnosis, implement comprehensive quality control measures, reduce turnaround times, and boost productivity with more efficient workflows. The Ibex suite includes solutions which are for Research Use Only (RUO) in the United States and not cleared by the FDA. Multiple solutions are CE marked (IVDD and IVDR) and registered with the UK MHRA. For more information, including indication for use and regulatory approval in other countries, contact Ibex Medical Analytics.

Results Published in the Journal Pathology Kameda Adopts Ibex's Galen Prostate and Galen Breast to Support Pathologists in Primary Diagnosis BOSTON and CHIBA, Japan, May 20, 2024 /PRNewswire/ -- Ibex Medical Analytics (Ibex), a global leader in AI-powered cancer diagnostics, and Kameda Medical Center (Kameda), a leading Japanese institute at the pinnacle of healthcare innovation, today announced the publication of a clinical study evaluating Ibex's Galen™ platform, published in the peer-reviewed journal Pathology1, which demonstrated excellent outcomes in detecting cancer and other pathologies in prostate and breast biopsies. The artificial intelligence (AI)-powered platform has subsequently been deployed at Kameda and is now supporting their pathologists in routine practice, integrated with their Philips IntelliSite Pathology Solution. Ibex Logo Kameda Medical Center Logo

CAROLINA, Puerto Rico, May 14, 2024 /PRNewswire/ -- CorePlus , a precision pathology organization, announced today that it is the first laboratory in the world to operationalize the Techcyte AI algorithm and quality control workflow for cytology-based cervical cancer screening. After more than two years of clinical collaboration with Techcyte, we have achieved the level of precision and accuracy necessary to deploy this tool for use with our patients to provide 100% quality control of all Pap tests, which goes well beyond the regulatory mandates. Continue Reading Figure 1. Techcyte's gallery view. We are fortunate to have been able to include Puerto Rican women in the validation of the algorithm. Ethnic diversity is a key to eliminating potential algorithmic bias. Including this subset of the population, ensures that Hispanic women will be well represented. This is important as Hispanics are becoming a significant percentage of the US population." said Mariano de Socarraz, Founder and CEO of CorePlus. Puerto Rican women faced an increase in the incidence of cervical cancer rate from 9.2 to 13 cases per 100,000 between 2001 to 20171. Early detection is paramount to provide initial therapeutic intervention and ensure better quality of life and impact healthcare cost. Juan C. Santa-Rosario, M.D., CorePlus' Chief Medical Officer states, "Our validation study included digitization of more than 1,500 cases scanned on the Epredia P1000 with water immersion at different modalities and was conducted by Dr. María del Mar Rivera-Rolón, our Board-Certified Cytopathologist. Now we will be able to review 100% of Pap tests processed at our laboratory using the Techcyte AI-assisted tool with the intent of providing more accurate results and promoting patient safety." "CorePlus is one of the most innovative organizations in the world at implementing digital pathology solutions. We are thrilled they will be using our AI-based cervical cytology software to have a real impact on the health of women in Puerto Rico and throughout the world. We appreciate their collaboration and shared mission to make a positive impact for lab professionals and the patients they serve." said Ben Cahoon, CEO of Techcyte. CorePlus is committed to deploying new and disruptive technologies that will benefit our patients, physicians, and the healthcare ecosystem at large. About CorePlus CorePlus Servicios Clínicos y Patológicos, LLC, a precision pathology organization, a leader in the transformation of pathology to digital pathology and the use of Artificial Intelligence (AI) algorithms since 2020. CorePlus is a high complexity CLIA certified laboratory with facilities in Carolina and Ponce, Puerto Rico. CorePlus has implemented and validated the AI-powered solutions pursuant to CLIA laboratory developed test (LDT) regulations and College of American Pathology (CAP) guidelines. The CorePlus Team of Board-certified pathologists became the first in the United States and the Americas to operationalize Ibex's Galen Prostate solution June of 2020. Visit for more information. About Techcyte Founded in 2013, Techcyte is transforming the practice of pathology with a unified pathology platform that digitizes lab workflows and offers AI tools that improve the efficiency and accuracy of diagnostic testing. Our mission is to positively impact the health of humans, animals, and the environment through the use of artificial intelligence. We do that by partnering with best-in-class labs, whole slide scanner manufacturers, AI vendors, diagnostic companies, hardware manufacturers, and solution providers. Together, we aim to deliver a unified clinical and anatomic pathology platform to labs and clinics around the world. Visit for more information. About Epredia Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE: 6523) offers a unique array of end-to-end instruments for pathology workflows including tissue processors, microtomes, embedding stations, and a range of 3DHistech developed whole slide scanners from the single slide Pannoramic Desk II to the Pannoramic 1000 scanner. These scanners offer a single slide to 1000 slide capacity and a throughput of up to 85 slides per hour, including overnight scanning. Visit for more information. Ortiz, A.P., Ortiz-Ortiz, K.J., Colon-Lopez, V., Tortolero-Luna, G., Torres-Cintron, C.R.,Wu, C.F., Deshmukh, A.A., 2021. Incidence of Cervical Cancer in Puerto Rico, 2001-2017. In JAMA Oncology (Vol. 7, Issue 3, pp. 456–458). American Medical Association. 10.1001/jamaoncol.2020.7488. SOURCE CorePlus Servicios Clinicos y Patologicos, LLC